Table 1. Value of Financial Penalties and Duration of Illegal Activity.
| Companya | Value of penalties, total $, in thousandsb | No. of penalties | Penalty amount, mean $, in thousands | Penalties, % of total revenues (rank)c | Duration of illegal activity associated with penalties, mean, y |
|---|---|---|---|---|---|
| GlaxoSmithKline | 9 775 419 | 27 | 362 053 | 1.55 (2) | 7.22 |
| Pfizer | 2 910 581 | 18 | 161 699 | 0.36 (11) | 5.67 |
| Johnson & Johnson | 2 668 326 | 15 | 177 888 | 0.28 (13) | 6.08 |
| Abbott Laboratories | 2 581 585 | 11 | 234 690 | 0.75 (6) | 6.36 |
| Merck | 2 094 026 | 11 | 209 403 | 0.40 (9) | 6.13 |
| Eli Lilly | 1 775 031 | 7 | 253 576 | 0.59 (7) | 6.14 |
| Schering-Ploughd | 1 645 186 | 12 | 137 099 | 2.05 (1) | 6.18 |
| Wyethd | 1 614 355 | 7 | 230 622 | 1.15 (4) | 8.71 |
| Bristol Myers Squibb | 1 389 197 | 12 | 115 766 | 0.50 (8) | 5.83 |
| Novartis | 1 198 088 | 11 | 108 917 | 0.18 (16) | 6.55 |
| AstraZeneca | 1 172 185 | 10 | 117 219 | 0.28 (14) | 8.30 |
| Amgen | 945 034 | 9 | 105 004 | 0.39 (10) | 9.78 |
| Allergand | 660 604 | 1 | 660 604 | 1.16 (3) | 7.00 |
| Bayer | 602 688 | 13 | 46 361 | 0.09 (19) | 4.00 |
| Mylan | 227 800 | 6 | 37 967 | 0.30 (12) | 4.67 |
| Sanofi-Aventis | 535 923 | 10 | 53 592 | 0.10 (18) | 6.50 |
| Boehringer Ingelheim | 416 439 | 7 | 59 491 | Not applicablee | 5.86 |
| Forest Laboratoriesd | 383 452 | 3 | 127 817 | 0.88 (5) | 5.33 |
| Actavis (Watson) | 77 312 | 2 | 38 656 | 0.09 (17) | 11.00 |
| Roche Group | 67 000 | 1 | 67 000 | 0.01 (21) | 5.00 |
| Genzymed | 56 152 | 2 | 28 076 | 0.19 (15) | 5.00 |
| Perrigo | 7816 | 1 | 7816 | 0.02 (20) | 1.00 |
Four firms were not found to have penalties for illegal activities during the sample period: Biogen Idec, Celgene, Gilead Sciences, and Hospira.
Total dollar value from 2003 through 2016, adjusted for inflation in 2016 dollars (the last year of data collection).
Sum of yearly revenues for the duration of firm existence over the study period (2003-2016), adjusted for inflation in 2016 dollars.
Six companies were acquired before 2016: Forest Laboratories in 2014 and Allergan in 2015 (acquired by Actavis [Watson]), Schering-Plough in 2009 (acquired by Merck), Wyeth in 2009 and Hospira in 2015 (acquired by Pfizer), and Genzyme in 2011 (acquired by Sanofi).
Boehringer Ingelheim is private. Revenues were not available to calculate penalties as a percentage of revenue.